Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.

Saved in:
Bibliographic Details
Title: Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.
Authors: Hassaniazad M; Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran., Farshidi H; Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran., Gharibzadeh A; Social Determinants in Health Promotion Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran., Bazram A; Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran., Khalili E; Student Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran., Noormandi A; Department of Inpatient Services, Iran Food and Drug Administration, Tehran, Iran., Fathalipour M; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.; Endocrinology and Metabolic Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Source: Journal of medical virology [J Med Virol] 2022 Jul; Vol. 94 (7), pp. 3184-3191. Date of Electronic Publication: 2022 Mar 24.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1096-9071
DOI:10.1002/jmv.27724